NOVARTIS for NOVARTIS
What was lobbied
11 issue areas, each in the filer's own words, with who lobbied on it and where.
Energy/Nuclear ENG
Increasing domestic supply of Actinium 225
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| LEO A FARBER | — |
Science/Technology SCI
Artificial intelligence Data and digital technologies
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| SARAH HALLER | — |
| SHELLY MUI-LIPNIK | — |
| COURTNEY PIRON | — |
Labor Issues/Antitrust/Workplace LBR
The Competition and Antitrust Law Enforcement Reform Act (S.225): Anti-Trust Reform
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| COURTNEY PIRON | — |
Trade (domestic/foreign) TRD
Access to Medicines Issues Biopharmaceutical Innovation Policies CFIUS China Agreement Free Trade Agreements - Intellectual Property and Transparency Provisions Global Health Issues India, China and Canada IP and Market Access Issues Intellectual property International Market Access and Intellectual Property Issues Pharmaceutical Supply Chain Pricing and reimbursement policy issues Quality of Medicines Regulatory Cooperation Sub-standards Medicines Supply chain and China Task Force policy issues Tariffs Trade Policy UK Agreement US Swiss Trade Agreement USMCA USTR Special 301 Report/National Trade Estimate WTO IP Waiver
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Taxation/Internal Revenue Code TAX
ACA Pharmaceutical Industry Fee Exclusions Base Erosion Anti-Abuse Tax (BEAT) OECD Digital Tax Orphan Drug Tax Pharmaceutical supply chain incentives Tax Treaties Thin Capitalization Rules 163(j) R&D Amortization U.S. Corporate Tax Administration's FY 2022 Revenue Proposals Restrict deductions of excessive interest of members of financial reporting groups for disproportionate borrowing in the United States (Sec. 163(n)) Stopping Harmful Inversions and Ending Low-Tax Developments (SHIELD)
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Copyright/Patent/Trademark CPT
Bayh-Dole Act Biopharmaceutical Intellectual Property Biosimilars BPCIA Data Exclusivity Intellectual Property Issues in Response to coronavirus Patents Section 101 Compulsory licenses Antitrust Legislation S.225, Competition and Antitrust Law Enforcement Reform Act H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 S.1435, Affordable Prescriptions for Patients Act of 2021
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Health Issues HCR
340B Drug Discount Program AMP Cap Biosimilar approval and reimbursement policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions BLOCKING Act Buy American and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients Cell, gene and radioligand therapies COVID-19 21st Century Cures Act 2.0 Diversity in Clinical Trials Drug cost and pricing policy issues Drug Importation and counterfeiting policy issues Drug shortages policy issues Drug vial size policy issues FDA modernization policy issues Foreign manufacturing policy issues FY 2022 Labor-HHS Appropriations Medicaid Generics Penalty Fix Medicaid Payment Reform Notice of Benefit Payment Parameters (NBPP) Orphan Drugs Outcomes based contracting/value based arrangements Part B Home Infusion Patient assistance program policy issues PDUFA, BSUFA, GDUFA Pharmaceutical quality Pharmaceutical supply chain Priority Review Voucher (PRV) Regulatory efficiencies policy issues Transparency policy issues Vaccines H.R.3, Elijah E. Cummings Lower Drug Costs Now Act H.R.133, Consolidated Appropriations Act for FY 2021 H.R.1319, American Rescue Plan Act of 2021 Defense Production Act Advanced Research Projects Agency for Health (ARPA-H) Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 Comprehensive Immunosuppressant Drug Coverage for Kidney Transplant Patients Act of 2020 S.1427, HR 2869 - Increasing Access to Biosimilars Act of 2021 H.R.2815, The BIOSIM Act H.R.2855, Star Rating for Biosimilars Act S.164, Advancing Education on Biosimilars Act of 2021 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement White House National Biodefense Strategy
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Veterans VET
Health care collaboration opportunities
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| JOSEPH MCGOWAN | — |
| COURTNEY PIRON | — |
Foreign Relations FOR
CFIUS Reform Foreign Agents Registration Act (FARA) Reform
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| SHELLY MUI-LIPNIK | — |
| COURTNEY PIRON | — |
Medicare/Medicaid MMM
AMP Cap Anti-Kickback Statute policy issues ASP reporting policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Drug Pricing Drug wastage rebates policy issues Innovative Pharmaceuticals (including cell, gene and radioligand therapies), Biosimilars and Generics Medicaid Medicaid rebates and waiver policy issues Medicare Part A, B and D Non-covered drugs policy issues Outcomes based Contracting/value based arrangements Patient Cost-Sharing and Smoothing Reimbursement for cell therapy products Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals Transparency policy issues Medicare Negotiations
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Budget/Appropriations BUD
Biosimilars Drug Pricing Fiscal year 2022 Appropriations Importation Value of Medicine H.R.133, Consolidated Appropriations Act for FY 2021 H.R.1319, American Rescue Plan Act of 2021 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement Prescription Drug User Fee Act (PDUFA) VII Priorities Advanced Research Projects Agency for Health (ARPA-H)
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.